EIPICO board members visit EIPICO3 facilities .
The company's board members has conducted today a visit to EIPICO3 factory, touring its various production areas.
They emphasized that EIPICO, through this factory, provides significant support in localizing and deepening the Biologicals and Biosimilars industry in Egypt
This marks a new era for EIPICO in the pharmaceutical industry in Egypt, as the factory is the first in Egypt to produce Biosimilar & Biologicals from cell culture up to finished product, with investment of 100 $ million
EIPICO3 factory is the first of its kind in Egypt and the MENA region to manufacture Biologicals and Biosimilars completely from the cell line up to the finished product.
They also emphasized that EIPICO3 represents a major leap forward and will provide a great opportunity for our youth to work with the most worldwide updated technology in manufacturing biological products, thus enhancing their expertise in an unprecedented manner
At the conclusion of the visit, the Board of Directors expressed their appreciation to Dr. Ahmed Kelani, Chairman and Managing Director of EIPICO, and his team for their tremendous efforts in implementing this outstanding project, with investment of $100 million.
It is worthy to mention that the EIPICO3 factory has been licensed for operation by the Egyptian Drug Authority ( EDA( and the Industrial Development Authority) IDA) , coinciding with the launch of ADALIMAB, the first biological product to be produced at the factory.
